AzTrials
AzTrials

DysbiosisNCT06877585

Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels

An observational study of Dysbiosis, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Gut dysbiosis is frequently characterized by decreased microbial diversity and alterations in the abundance of certain microbial species. In individuals with chronic kidney disease (CKD), dysbiosis and metabolic imbalances are prevalent, contributing to the buildup of gut-derived retention solutes and metabolites in… Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Dysbiosis
How many people
58 participants
Where
1 siteTaiwan
Study dates
1 Apr 2025to 31 Dec 2025
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: hemodialysis patients

Who may be able to join

  • age 18-80 years and
  • diagnosed with CKD stage V
  • currently receiving hemodialysis treatment>3 months

Who cannot join

  • pregnant or nursing women
  • patients with kidney transplant
  • severe infections
  • severe cardiac diseases
  • liver diseases
  • malignancy
Show all 13Show fewer
  • autoimmune disorders
  • severe malnutrition
  • consumed any type of pre-or probiotics
  • had antibiotic therapy within 1 month
  • diagnosed irritable bowel syndrome
  • Crohn's disease
  • ulcerative colitis

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • Tungs' Taichung Metroharbour Hospital

    Taichung, Wuqi District, 435

Other trials in Taiwan

About this study

Official title: Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels in Hemodialysis Patients

Gut dysbiosis is frequently characterized by decreased microbial diversity and alterations in the abundance of certain microbial species. In individuals with chronic kidney disease (CKD), dysbiosis and metabolic imbalances are prevalent, contributing to the buildup of gut-derived retention solutes and metabolites in the bloodstream. Research has consistently shown that CKD patients exhibit lower levels of beneficial gut bacteria. However, the specific functional changes in gut microbiota and their interactions with levels of uremic toxins in hemodialysis (HD) patients remain incompletely understood. This study seeks to explore the association of fecal metagenomics and targeted metabolomics in a cohort of 60 patients with different levels of to characterize the complex interplay between the gut microbiome and fecal and serum metabolites.

Read the detailed description

Patients and Study Design

Sixty HD patients will be enrolled, from dialysis unit, Renal Division of The Tungs' Taichung Metroharbour Hospital. The written informed consent to take part in the study is obtained from each participant after being informed on study design and aims. The experimental protocol will send to the Ethical Committees of IRB for approval. Inclusion criteria are age 18-80 years and diagnosed with CKD stage V (currently receiving hemodialysis treatment>3 months). Exclusion criteria included pregnant or nursing women; patients with kidney transplant, severe infections, severe cardiac diseases and liver diseases, malignancy, autoimmune disorders, severe malnutrition; consumed any type of pre-or probiotics or had antibiotic therapy within 1 month of study commencement; diagnosed irritable bowel syndrome, Crohn's disease, or ulcerative colitis; receiving or have received bowel radiation or had large bowel resection The participants will receive dietary instructions and are encouraged to maintain stable dietary intake, which is quantified by nutritional questionnaires during patient interviews. The questionnaires gathered information about the weekly amount and frequency of food and beverage consumption. Data regarding the nutrient composition of the different foods are obtained using the tables of the Institute of Nutrition and Food Safety, National Taiwan University.

Sample Collection, Preparation and Analysis Blood samples are collected separately from each participant. Blood samples are collected after an 8 to 12-hour fasting period, using sodium fluoride tubes, and kept on ice until transfer to the research laboratory. Once there, the samples are centrifuged at 3,000×g for 15 minutes at 4°C. The serum is then transferred to sterile tubes and stored at -20°C for future analysis.

investigators measure serum levels of acetate, propionate, butyrate, and valerate, along with branched-chain SCFAs such as isobutyrate and isovalerate. These metabolite profiles are analyzed using ultraperformance liquid chromatography-mass spectrometry (UPLC-MS). In brief, 100 μL of each serum sample is mixed in 1.5-mL microtubes with 20 mg of NaCl, 10 mg of citric acid, 20 μL of 1 M HCl, and 100 μL of butanol. The mixture is vortexed for 2 minutes and then centrifuged at 18,000×g for 15 minutes. The resulting supernatant is transferred to fresh microtubes for analysis.

Measurement of uremic toxins Investigators measure total uremic toxin levels rather than free levels. The concentrations of total indoxyl sulfate, p-cresyl sulfate, indole-3-acetic acid (IAA), and hippuric acid are centrally quantified using a previously described method [19]. Briefly, for binding competition, 200μl serum to which investigators added 20μl 0.50mM 1-naphthalenesulfonic acid (internal standard) was vortex-mixed with 250μl 0.24M sodium octanoate (binding competitor).After incubation at room temperature for 5min, investigators added 2ml cold acetone to precipitate proteins. Following vortex-mixing and centrifuging at 4 ◦C, 1860×g for 20 min, the supernatant was transferred to 12mm×100mm, GL 14 glass test tubes and 2ml dichloromethane was added. After vortex-mixing and centrifuging at 4 ◦C, 1860×g for 10min, 200μl of the upper layer was transferred to glass autosampler vials, followed by addition of 20μl 1M HCl and 15μl was injected onto the HPLC. The HPLC analysis was performed on an Agilent 1100 series LC (Santa Clara, CA),and Agilent ChemStations software were used for the chromatographic analysis. The separation was carried out on a ZORBAX SB-C18 Solv Saver Plus HPLC column (5 μm, 3.0 mm×150 mm).at a flow rate of 0.6 ml/min. Mobile phase A is 0.2% trifluoroacetic acid in Milli-Q water and mobile phase B is 0.2% trifluoroacetic acid in acetonitrile. The analytical method consists of an isocratic run with 92% mobile phase A for 23 min.. Each analytical run was followed by a 1.3 min washout gradient to 100% B. Column temperature was 25 ◦C, and autosampler tray temperature was 6 ◦C. Investigators quantified the analytes by using the analyte to standard peak area ratio on a Agilent 1100 High Performance Fluorescence detector G1321A and Agilent 1100 Series UV-Visible detectors G1314A. Detector settings were λex 260 nm/λem288nm for p-cresyl sulfate and λex 280 nm/λem 390nm for indoxyl sulfate, indole-3-acetic acid and internal standard. Hippuric acid was monitored by UV-Vis detector at 254 nm. Quantitative results are obtained and calculated in terms of their concentrations (mg/L).

Fecal microbiota profile Sample Collection Qualified stool samples are self-collected in sterile frozen tubes by subjects and were transported immediately to the laboratory where they were stored at - 80 ◦C for further testing.

DNA Extraction and Sequencing Genomic DNA from fecal samples is extracted using the QIAGEN DNA Stool Fast Kit (QIAGEN) according to the manufacturer's guidelines. The quality of the extracted metagenomic DNA is assessed through 1.0% agarose gel electrophoresis and spectrophotometric analysis (measuring the optical density at a 260/280 nm ratio). For the extracted DNA to be considered suitable, the concentration has to exceed 20 ng/μl, with a 260/280 nm ratio within the range of 1.8 to 2.0. The variable region 4 (V4) of the bacterial 16S rRNA gene is amplified through polymerase chain reaction (PCR) with bacterial/archaeal primers 515F/806R, including barcodes for sample identification. The resulting amplicons are purified using the GeneJET Gel Extraction Kit (Thermo Scientific) and quantified with a Qubit dsDNA HS Assay Kit on a Qubit 2.0 Fluorometer (Qubit). Sequencing libraries are prepared using the NEBNext® Ultra™ DNA Library Prep Kit for Illumina (NEB), following the manufacturer's protocol. The purified libraries are quantified, normalized, pooled, and then use for cluster generation and sequencing on an Illumina HiSeq 2500 platform to produce 250 bp paired-end reads.

Paired-end reads are merged using FLASH v1.2.7, and quality filtering is performed using the QIIME 1.7 pipeline with Python scripts. Chimeric sequences were removed by UCHIME. The processed reads (effective tags) are clustered into operational taxonomic units (OTUs) at 97% sequence identity using UPARSE, and taxonomic classification is assigned based on the SILVA database. To assess the phylogenetic relationships of different OTUs, multiple sequence alignments are performed using PyNAST v1.2 against the SILVA database, and a phylogenetic tree was constructed using FastTree.

Alpha diversity is estimated by species richness using the Chao1 index at the OTU level. A rarefaction curve is generated by randomly selecting a subset of sequencing data from each sample to represent the number of observed species, and a species accumulation curve is plotted to show the occurrence of new OTUs (species) with continuous sampling. For beta diversity, Bray-Curtis dissimilarities at the OTU level are calculated and analyzed using the vegan package. Principal coordinate analysis (PCoA) is conducted based on Bray-Curtis distances, and both weighted and unweighted UniFrac parameters are computed through the QIIME pipeline. Non-metric dimensional scaling (NMDS) is performed using the weighted correlation network analysis (WGCNA), stat, and ggplot2 packages in R by transforming a distance matrix of weighted and unweighted UniFrac parameters into a new set of orthogonal axes. All analyses are conducted using in-house R scripts, unless otherwise specified.

Functional composition of metagenomes is predicted from 16S rRNA data using the PICRUSt software with Python scripts. A precomputed table of gene copy numbers for each gene family from sequenced bacterial and archaeal genomes, based on the IMG database, along with a phylogenetic tree from the Greengenes database, is used for gene content prediction.

Conditions
Dysbiosis
Keywords
gut microbiome, gut dysbiosis, hemodialysis patients, indoxyl sulfate
Medical subject headings
Dysbiosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06877585
Study groupRoleWhat they receive
Hemodialysis PatientsThis study seeks to explore the association of fecal metagenomics and targeted metabolomics in a cohort of 60 patients with different levels of to characterize the complex interplay between the gut microbiome and fecal and serum metabolites.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fecal microbiota profile

    Alpha diversity, Beta diversity and functional composition of metagenomes is predicted from 16S rRNA data using the PICRUSt software with Python scripts

    Measured: 1 years

Secondary outcomes (5)
  1. Measurement of serum uremic toxins

    Quantification of p-cresyl sulfate concentrations.

    Measured: 1 years

  2. Evaluation of short-chain fatty acids(SCFAs) and branched-chain SCFAs

    We measure serum levels of acetate, propionate, butyrate, and valerate, along with branched-chain SCFAs such as isobutyrate and isovalerate.

    Measured: 1 years

  3. Measurement of serum uremic toxins

    Quantification of total indole sulfate concentrations

    Measured: 1 years

  4. Measurement of serum uremic toxins

    Quantification of indole-3-acetic acid concentrations

    Measured: 1 years

  5. Measurement of serum uremic toxins

    Quantification of hippuric acid concentrations

    Measured: 1 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Mar 2025
  2. Study start1 Apr 2025
  3. Primary completion31 Dec 2025
  4. Study completion31 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
58 participants (actual)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT06877585
Sponsor's protocol ID
113097
Other IDs
TTMHH-R1140050
Status last verified
May 2026
First submitted
10 Mar 2025
Last updated
13 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: all collected IPD, all IPD that underlie results in a publication

Publications

  • DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006 Jul;72(7):5069-72. doi: 10.1128/AEM.03006-05.

    PubMed 16820507
  • Markowitz VM, Chen IM, Palaniappan K, Chu K, Szeto E, Grechkin Y, Ratner A, Jacob B, Huang J, Williams P, Huntemann M, Anderson I, Mavromatis K, Ivanova NN, Kyrpides NC. IMG: the Integrated Microbial Genomes database and comparative analysis system. Nucleic Acids Res. 2012 Jan;40(Database issue):D115-22. doi: 10.1093/nar/gkr1044.

    PubMed 22194640
  • Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013 Sep;31(9):814-21. doi: 10.1038/nbt.2676. Epub 2013 Aug 25.

    PubMed 23975157
  • Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R. UniFrac: an effective distance metric for microbial community comparison. ISME J. 2011 Feb;5(2):169-72. doi: 10.1038/ismej.2010.133. Epub 2010 Sep 9. No abstract available.

    PubMed 20827291
  • Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol. 2009 Jul;26(7):1641-50. doi: 10.1093/molbev/msp077. Epub 2009 Apr 17.

    PubMed 19377059
  • Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics. 2010 Jan 15;26(2):266-7. doi: 10.1093/bioinformatics/btp636. Epub 2009 Nov 13.

    PubMed 19914921
  • Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6. doi: 10.1093/nar/gks1219. Epub 2012 Nov 28.

    PubMed 23193283
  • Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013 Oct;10(10):996-8. doi: 10.1038/nmeth.2604. Epub 2013 Aug 18.

    PubMed 23955772
  • Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011 Aug 15;27(16):2194-200. doi: 10.1093/bioinformatics/btr381. Epub 2011 Jun 23.

    PubMed 21700674
  • Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010 May;7(5):335-6. doi: 10.1038/nmeth.f.303. Epub 2010 Apr 11. No abstract available.

    PubMed 20383131
  • Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011 Nov 1;27(21):2957-63. doi: 10.1093/bioinformatics/btr507. Epub 2011 Sep 7.

    PubMed 21903629
  • Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012 Aug;6(8):1621-4. doi: 10.1038/ismej.2012.8. Epub 2012 Mar 8.

    PubMed 22402401
  • de Loor H, Poesen R, De Leger W, Dehaen W, Augustijns P, Evenepoel P, Meijers B. A liquid chromatography - tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. Anal Chim Acta. 2016 Sep 14;936:149-56. doi: 10.1016/j.aca.2016.06.057. Epub 2016 Jul 2.

    PubMed 27566350
  • Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch. 2020 Mar;472(3):303-320. doi: 10.1007/s00424-020-02352-x. Epub 2020 Feb 17.

    PubMed 32064574
  • Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013 Feb;83(2):308-15. doi: 10.1038/ki.2012.345. Epub 2012 Sep 19.

    PubMed 22992469

Questions about this trial

What is this clinical trial studying?

An observational study of Dysbiosis, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fecal microbiota profile (time frame: 1 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06877585, which also lists 29 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in